News

For the first time worldwide, an artificial intelligence (AI) tool is clinically validated for breast cancer diagnosis. Institut Curie and Ibex Medical Analytics, a pioneer in AI-based cancer diagnosis, demonstrate the performance, reliability and clinical application of an AI algorithm for breast biopsy diagnosis. These results were just published in the journal npj breast cancer.

Valeo and the Carnot Institute CEA LETI signed an agreement to collaborate on the next generations of power electronics, which are at the heart of the challenges facing tomorrow's electric mobility.

Carnot CEA LIST developed a real-time livestock monitoring system that leverages the analysis of video streams to identify individual animals and specific behaviors that can indicate disease or whether an animal is in heat, for example.

In 2021, Institut Curie start-ups raised 140.6 million euros. This impressive amount reaffirms Institut Curie's unique position as a key player in French innovation, driven by one ambition: to transform research into concrete applications for patients.

Visual inspection is the most common technique used for the maintenance of civil engineering structures like bridges. While it does offer the advantage of being non-destructive, visual inspection also depends on inspectors who interpret photographs and write up inspection reports—which then become the main source of information used by the operators of these structures to optimise their maintenance plans. SOCOTEC leads the project called SOFIA in partnership with Carnot CEA LIST Insitute to develop a groundbreaking inspection tool that will bring the power of artificial intelligence to machine vision. Together in a consortium with CEA LIST, SOFIA won a French call launched by CEREMA on “connected bridges”.

The two organizations will share a joint roadmap to create long-term disruptive technologies in France and Europe. The first scientific and technological areas of focus include virtual twin experiences in health and cybersecurity. The alliance aims to support French and European ecosystems in these domains and the digital trust dynamic. Alliance builds on the existing 20-year collaboration between the two organizations that has already helped advance science and innovation in digital technology.

Clearmatics Technologies develops blockchain-based solutions for the financial markets. The company turned to Carnot CEA LIST Institute for support developing solutions that meet the unique needs of financial transactions.

Carnot CEA Leti Institute has been developing photonics on silicon nitride for several years now. Today, the technology is mature enough to address growing demand for high-performance chips. 

AVATAR MEDICAL, spin-off from Carnot Curie Cancer Institute and Carnot Pasteur MS Institute, announces a €1.2 million fundraising for its virtual reality solution that aims to radically change the way surgeons access, interpret and act on clinical data contained in medical images.

Today, medical students can practice surgical procedures on "digital doubles" of patients in a safe, controlled virtual reality environment. When combined with haptic interfaces (from the Greek word haptomai, meaning "touch"), these tools can rapidly bring interns up to speed for clinical examinations on real patients.

In 2020, researchers at Inserm, Université de Paris, and Assistance Publique–Hôpitaux de Paris (AP-HP), in collaboration with the university hospital organisation Institut Imagine (Hôpital Necker-Enfants malades AP-HP), which has been granted “Institut Carnot” certification through The Rockefeller University and the Howard Hughes Medical Institute in New York, identified the leading genetic and immunological causes responsible for at least 15% of serious forms of Covid-19. Today, this same French and American team, jointly lead by Jean-Laurent Casanova and Laurent Abel* at the Institut Imagine and The Rockefeller University, is joining forces with Cerba HealthCare, a leading stakeholder in medical diagnostics, to transform these discoveries into clinical applications and screen individuals who are more likely to develop a severe form of the disease and tailor their treatment accordingly.

IQVIA, world leader in the healthcare data market, and the CALYM Carnot Institute, Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field, have entered into a strategic partnership around a hematology database, the HemSys software. As part of this exclusive partnership, IQVIA is making its expertise and network available to CALYM, in the valorization of health data for research purposes and access to the market for therapeutic innovations.